MedTrace Logo

Measurement of Intestinal Permeability in Intensive Care Patients With Single or Multiple Organ Failure

NCT06845865 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 126

Last updated 2025-05-02

No results posted yet for this study

Summary

Multivisceral failure syndrome (MVFS) in humans is associated with a very high risk of mortality, ranging between 30 and 50%. This syndrome is associated with significant systemic inflammation and a high risk of bacteremia, the origin of which is not always identified. Among the possible causes of bacteremia, digestive translocation is the most probable but has not been formally proven to date. This translocation is made possible by the numerous cellular and metabolic alterations secondary to MVFS, which can lead to increased intestinal barrier permeability. Intestinal permeability is currently not systematically evaluated in clinical practice in humans.

This increased intestinal permeability, associated with the presence of inflammatory markers and a septic state, has been studied in several animal models ranging from the fruit fly (Drosophila) to the mouse. These studies have shown a high risk of mortality associated with increased intestinal permeability.

We propose to use this methodology in intensive care patients with at least one organ failure to investigate the link between increased intestinal permeability and survival chances.

Conditions

  • Multivisceral Failure Syndrome
  • Monovisceral Failure
  • Infection in ICU

Interventions

DIETARY_SUPPLEMENT

enteric dyed solution

Oral administration of 0.5 mg/kg of body weight of food coloring dye

Sponsors & Collaborators

  • Centre Borelli UMR 9010

    collaborator NETWORK

  • Direction Centrale du Service de Santé des Armées

    lead OTHER

Principal Investigators

  • Clément DUBOST, MD, PhD · National teaching army hospital BEGIN (Hôpital National d'Instruction des Armées BEGIN)

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-20
Primary Completion
2029-02-28
Completion
2029-04-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06845865 on ClinicalTrials.gov